

Oxular announces issued UK Patent related to its proprietary Ocular Drug Delivery Device

02 November 2016 – Oxular Limited, the Oxford-based retinal therapeutics company, today announced the UK Intellectual Property Office granted GB-B-2531910 in a patent titled “Ophthalmic delivery device.”

GB-B-2531910 provides an ophthalmic injection device designed for self-actuated injection of a therapeutic composition through a needle into the suprachoroidal or supraciliary space. A pressurized injection material is automatically discharged when the distal tip of the needle reaches the depth of the target tissue space. The device thereby enables one-handed, simple injection into the suprachoroidal space or supraciliary space regardless of the thickness variability in overlying scleral tissue.

We strongly believe this ocular drug delivery technology enables Oxular’s unique treatment approach which aims to access specific small spaces in the eye and to provide unique drug distribution to tissues specifically involved in retinal diseases. The drug delivery device is paired with companion drug compositions to form a complete system which is engineered to meet the demands of current market trends toward longer treatment durations and less invasive delivery.

Enquiries

Ben Atwell

Tel: +44 (0) 2037 271390

About Oxular Limited

Oxular is developing novel retinal treatments engineered to access specific small spaces in the eye and to provide unique drug distribution to tissues specifically involved in retinal diseases. The innovative approach aims to increase therapeutic effectiveness, reduce side-effects and minimize frequency of treatments. Oxular’s product development pipeline includes treatments for prevalent retinal diseases, such as diabetic macular edema, as well as rare and orphan indications (www.oxular.com).